Mergers and acquisitions Archives -

The chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right

Celgene investors’ CVR payment looks rocky, as FDA rejects ide-cel file

https://pharmaphorum.com/news/celgene-investors-merger-payment-looks-rocky-as-fda-rejects-ide-cel-file/

News/ News/ Sales and Marketing

Saunders steps aside as AbbVie closes in on Allergan merger

Phil Taylor AbbVie, Allergan, Mergers and acquisitions, regulatory 0 Comment

The US competition regulator has finally approved the $63 billion takeover of Allergan by AbbVie, but only by

Saunders steps aside as AbbVie closes in on Allergan merger

https://pharmaphorum.com/news/saunders-steps-aside-as-abbvie-closes-in-on-allergan-merger/

News/ News/ News/ Oncology/ Sales and Marketing/ Top stories

Menarini bags blood cancer drug with $677M Stemline acquisition

Phil Taylor Elzonris, Haematology, Menarini Group, Mergers and acquisitions, Oncology, rare disease, Stemline Therapeutics 0 Comment

Italian drugmaker Menarini has agreed to buy Stemline Therapeutics, bolting on an already-approved drug for a rare form

Menarini bags blood cancer drug with $677M Stemline acquisition

https://pharmaphorum.com/news/menarini-bags-blood-cancer-drug-with-677m-stemline-acquisition/

News/ News/ Sales and Marketing/ Top stories

Antitrust delay scuppers Novartis’ $1bn generics sale to Aurobindo

Phil Taylor Aurobindo, generic, Mergers and acquisitions, Novartis 0 Comment

Novartis has called off the sale of two US generics businesses to India’s Aurobindo Pharma, part of a

Antitrust delay scuppers Novartis’ $1bn generics sale to Aurobindo

https://pharmaphorum.com/news/antitrust-delay-scuppers-novartis-1bn-generics-sale-to-aurobindo/

News/ News/ R&D

Lilly swoops on Dermira to claim Dupixent rival

Phil Taylor atopic dermatitis, dermatology, Dermira, Dupixent, Eli Lilly, Mergers and acquisitions, Regeneron, Sanofi 0 Comment

Eli Lilly agreed on Friday to buy dermatology specialist Dermira for $1.1 billion and its lead drug, a

Lilly swoops on Dermira to claim Dupixent rival

https://pharmaphorum.com/news/lilly-swoops-on-dermira-to-claim-dupixent-rival/

News/ News/ News/ R&D/ Sales and Marketing/ Top stories

Sumitomo, Roivant close $3 billion deal, forming Sumitovant

Phil Taylor Mergers and acquisitions, Roivant, Sumitomo Dainippon Pharma, Sumitovant Bopharma 0 Comment

A new international biotech – Sumitovant Biopharma – has been created after Sumitomo Dainippon’s strategic alliance with Roivant

Sumitomo, Roivant close $3 billion deal, forming Sumitovant

https://pharmaphorum.com/news/sumitomo-roivant-close-3-billion-deal-forming-sumitovant/

News/ News/ Sales and Marketing

Pfizer confirms generic medicines merger with Mylan

Phil Taylor generics, Mergers and acquisitions, Mylan, Pfizer 0 Comment

Pfizer and Mylan have announced an all-stock deal that would combine their off-patent medicines businesses, confirming speculation that

Pfizer confirms generic medicines merger with Mylan

https://pharmaphorum.com/news/pfizer-confirms-generic-medicines-merger-with-mylan/

News/ News

BMS will shed Otezla to push Celgene takeover through

Phil Taylor Bristol-Myers Squibb, Celgene, Mergers and acquisitions, Otezla, psoriasis 0 Comment

Bristol-Myers Squibb has opted to divest big-selling psoriasis drug Otezla to smooth the passage of its $74 billion

BMS will shed Otezla to push Celgene takeover through

https://pharmaphorum.com/news/bms-will-shed-otezla-to-push-celgene-takeover-through/

News/ News/ R&D/ R&D/ UK & Europe

Sanofi steals in to buy Ablynx for €3.9 billion

Andrew McConaghie Ablynx, European biotech, M&A, Mergers and acquisitions, Sanofi 0 Comment

Sanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which

Sanofi steals in to buy Ablynx for €3.9 billion

https://pharmaphorum.com/news/sanofi-steals-buy-ablynx-e3-9-billion/

Trending

Mergers and acquisitions

Login